儿童中药饮片临床运用及儿童药物研发中安全性问题研究

doi:10.19803/j.1672-8629.20240704

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (3): 324-328.
DOI: 10.19803/j.1672-8629.20240704

儿童中药饮片临床运用及儿童药物研发中安全性问题研究

贾志超, 胡思源^*, 李瑞本, 许雅倩

天津中医药大学第一附属医院,国家中医针灸临床医学研究中心,天津 300381

收稿日期:2024-09-10 出版日期:2025-03-15 发布日期:2025-03-17
通讯作者: ^*胡思源,男,博士,主任医师,中药临床评价方法学研究。E-mail：husiyuan1963@sina.com
作者简介:贾志超,男,在读博士,儿童常见病临床评价方法学研究。
基金资助:
国家科技重大专项重大新药创制（2020ZX09201-008）

Safety of Children’s Traditional Chinese Medicine Decoction Pieces in Clinical Application and Children’s Drug Development

JIA Zhichao ,HU Siyuan^*, LI Ruiben, XU Yaqian

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China

Received:2024-09-10 Online:2025-03-15 Published:2025-03-17

摘要/Abstract

摘要： 目的基于《中华人民共和国药典》（2020年版）一部（简称“《中国药典》”）中药饮片涉及儿童用药品种情况,为儿童中药饮片临床运用和药物研发提出参考建议。方法整理《中国药典》涉及儿童内容的饮片情况,分析存在的安全性问题。结果《中国药典》共收载中药饮片616种,明确涉及儿童人群的共26种。其中,有儿童主治且有儿童用法用量1种;有儿童主治但无儿童用法用量23种;无儿童主治但有儿童用法用量1种;儿童禁用1种。在有儿童主治的24种饮片中,涉及最多的主治为小儿疳病,标注为“有毒”的共3种,“有小毒”的共2种。结论建议加强对涉及儿童主治和儿童常用中药饮片的药学、毒理学等基础研究工作;重视临床中儿童药品不良反应的上报;进一步完善儿童用药相关标准,更好指导儿童中药饮片安全合理使用及儿童药物研发。

关键词: 儿童, 中药饮片, 安全性, 《中华人民共和国药典》, 药物研发

Abstract: Objective To give tips about the clinical application and development of traditional Chinese medicine decoction pieces for children based on the 2020 edition of the Pharmacopoeia of the People's Republic of China (ChP 2020). Methods The children’s decoction pieces specified in the ChP 2020 were categorized before safety risks were analyzed. Results The ChP 2020 covered a total of 616 types of traditional Chinese medicine decoction pieces, 26 of which were specifically related to children. Among them, one type had both indications and dosage for children, 23 had indications for children only, one had only dosage for children, and one was prohibited for children. Among the 24 herbal medicines with indications for children, the most commonly used indication was infantile malnutrition, and a total of 3 drugs were labeled as “toxic” and 2 as “slightly toxic”. Conclusion It is recommended that basic research on pharmacy and toxicology related to indications and TCM decoction pieces, adverse drug reactions in children be reported, and related standards be improved so as to facilitate safe medication and drug development.

Key words: Children, Traditional Chinese Medicine Decoction Pieces, Safety, Pharmacopoeia of the People’s Republic of China, Drug Development

中图分类号:

R985
994.11

贾志超, 胡思源, 李瑞本, 许雅倩. 儿童中药饮片临床运用及儿童药物研发中安全性问题研究[J]. 中国药物警戒, 2025, 22(3): 324-328.

JIA Zhichao, HU Siyuan, LI Ruiben, XU Yaqian. Safety of Children’s Traditional Chinese Medicine Decoction Pieces in Clinical Application and Children’s Drug Development[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 324-328.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240704

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I3/324

参考文献

[1] NMPA. Administrative Decree No. 202. Notice on the Issuance of Specifications for the Specifications of Chemical Drugs and Biological Products(关于印发化学药品和生物制品说明书规范细则的通知)[EB/OL].(2006-05-10)[2023-01-02].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20060510010101566_2.html.
[2] SAMR. Regulations on the administration of drug instructions and labels(药品说明书和标签管理规定)[EB/OL].(2006-03-15)[2023-01-02].https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_b1a64fa4b9314ecabadf3c6662b70c48.html.
[3] ZHANG Y, YE Y.Excavation and Evaluation of Signals of Antide-pressant-Related Suicide Adverse Events[J].Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志) , 2019, 38(1): 43-50.
[4] WANG XP, LIU LR, LUO QF, et al.Research Progress on Adverse Reactions of Clinical Antidepressants[J].Journal of Taizhou University(台州学院学报),2022, 44(6): 71-77.
[5] STONE M, LAUGHREN T, JONES ML, et al.Risk of Suicidality in Clinical Trials of Antidepressants in Adults: Analysis of Proprietary Data Submitted to US Food and Drug Administration[J].BMJ, 2009, 339(7718): b2880.
[6] XIE HZ, DENG XL, XIE YR, et al.Guidelines for the Diagnosis and Treatment of Mental Disorders(2020 edition)(精神障碍诊疗规范2020年版)[M].First edition. Beijing: People's Medical Publishing House, 2020: 169-171.
[7] PAN J, ZHANG W, ZHONG LT, et al.Establishment of Suicide Intervention Mechanism for Inpatients[J].Modern Hospitals(现代医院),2021, 21(5): 701-703.
[8] WANG C, XU DM, SHAO J, et al.Expert Consensus of Suicide Care Interventions for Psychiatric Inpatients with Depression[J].Chinese Journal of Nursing(中华护理杂志),2022, 57(18): 2181-2185.
[9] LIANG YZ, ZHOU FZ.Research Progress in Nursing Care of Suicidal Depression Patients[J].Internal Medicine(内科),2020, 15(1): 67-69.
[10] WANG J, CHEN L, JI ZP, et al.Risk Factors to Suicide Risk in Misdiagnosed Bipolar Disorder II Treated for Major Depressive Disorder[J].Chinese Journal of Nervous and Mental Diseases(中国神经精神疾病杂志),2015, 41(2): 65-70.
[11] MANGIONE CM, BARRY MJ, NICHOLSON WK, et al.Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement[J].JAMA, 2022, 328(15): 1534-1542.
[12] American Academy of Pediatrics. 2022 Recommendations for Preventive Pediatric Health care[J].Pediatrics, 2022, 150(1): e2022058044.
[13] ZHANG Y, HU DY, DING XP, et al.A Meta-Analysis of the Incidence of Suicidal Ideation in Chinese Patients with Depression[J].Journal of Nursing Science(护理学杂志),2022, 37(9): 103-106.
[14] Chinese Medical Association.Guidelines for Primary Diagnosis and Treatment of Depression(2021)[J].Chinese Journal of General Practitioners(中华全科医师杂志),2021, 20(12): 1249-1260.
[15] ZWIEBEL SJ, VIGUERA AC.Discontinuing Antidepressants: Pearls and Pitfalls[J].Cleve Clin J Med, 2022, 89(1): 18-26.
[16] ZHANG B, WU H, ZHANG XM, et al.Strategies for Clinical Pharmaceutical Care Based on the Improvement of "Warnings" in Chinese Patent Medicine Instructions[J].Journal of Beijing University of Traditional Chinese Medicine(北京中医药大学报) , 2022, 45(10): 979-984.

儿童中药饮片临床运用及儿童药物研发中安全性问题研究

Safety of Children’s Traditional Chinese Medicine Decoction Pieces in Clinical Application and Children’s Drug Development

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	郭东琪, 王浩, 白欣, 白建琦, 苏红梅, 张静茹, 郭宵飞, 赵小琪, 王敏, 王源, 张平. 基于多组学数据的孟德尔随机化分析鉴定椎间盘退变可成药靶点及中药预测[J]. 中国药物警戒, 2025, 22(3): 241-248.
[2]	康佳琪, 郭宵飞, 苏红梅, 白建琦, 朱宏伟, 白欣, 陈忻, 王浩, 赵小琪, 郭东琪, 王源, 张平. 补肾活血方对大鼠肾虚血瘀型腰椎间盘退变的干预作用[J]. 中国药物警戒, 2025, 22(3): 249-257.
[3]	胡琨, 黄卫国, 雷利利, 庞晓丛, 周颖, 崔一民. 硫唑嘌呤片致TPMT基因突变患者骨髓抑制1例分析[J]. 中国药物警戒, 2025, 22(3): 337-340.
[4]	李波, 徐柳, 谢雨晴, 王艺颖, 董帅, 廉洁, 李国栋, 曹卉娟. 中成药治疗新型冠状病毒感染安全性和有效性的伞状评价[J]. 中国药物警戒, 2025, 22(2): 155-161.
[5]	朱兰, 邵波, 朱彦, 戴洁, 钟诗琦. 已上市中成药说明书安全信息修订实践与思考[J]. 中国药物警戒, 2025, 22(2): 188-192.
[6]	聂晓璐, 赵厚宇, 霍东辉, 阎爱侠, 孙凤, 彭晓霞, 倪鑫, 詹思延. 基于真实世界数据与定量构效关系的儿童药源性免疫性血小板减少症研究[J]. 中国药物警戒, 2025, 22(1): 16-22.
[7]	孙一鑫, 王晨, 于玥琳, 郭鹏, 聂晓璐. 疫苗诱导的免疫性血栓性血小板减少症安全性监测系统综述[J]. 中国药物警戒, 2025, 22(1): 29-36.
[8]	戴梦茹, 李春, 张永欣, 卢宇, 程博宇, 冯伟红. 地黄药材中梓醇的含量测定研究[J]. 中国药物警戒, 2025, 22(1): 76-83.
[9]	邵波, 钟露苗, 成雨竹, 邓华, 朱兰. 银黄口服制剂安全性风险分析及思考[J]. 中国药物警戒, 2025, 22(1): 84-87.
[10]	赵秋月, 卫红涛, 李丹丹, 闫安, 邸宣. 阿加曲班注射液治疗急性缺血性脑卒中致消化道出血的不良反应分析[J]. 中国药物警戒, 2025, 22(1): 88-92.
[11]	于玟路, 张虹. 马钱子在骨伤科的应用研究进展[J]. 中国药物警戒, 2025, 22(1): 116-120.
[12]	江海燕, 周甜雨, 范潇予, 李万芳, 包捷, 靳洪涛. 抗肿瘤复方药物研发现状与挑战[J]. 中国药物警戒, 2024, 21(9): 961-966.
[13]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[14]	郑丽, 张凯华, 孙雪林. 小细胞肺癌治疗新药Tarlatamab药理作用及临床评价[J]. 中国药物警戒, 2024, 21(9): 1078-1080.
[15]	王岩, 滕晶晶, 杨同金, 夏新, 喻丹丹, 占海兵, 杨文明. 智脑胶囊长期毒性研究[J]. 中国药物警戒, 2024, 21(8): 878-883.